The Glimpse Group, Inc.
Foretell Reality, a Glimpse subsidiary company, to Develop VR Experiences and Tools to Support North-Star Care's Tele-Health Substance Use Disorder Program
NEW YORK, NY / ACCESSWIRE / July 20, 2021 / Foretell Reality, a wholly-owned subsidiary of The Glimpse Group, Inc. (NASDAQ:VRAR; "Glimpse"), and a provider of social Virtual Reality (VR) multi-person spaces, collaboration and interpersonal interaction, today announced a multiyear, six figure, software and services engagement with telehealth medical treatment provider North-Star Care (NSC).
Foretell Reality (https://foretellreality.com/) leverages VR to enhance interpersonal experiences in professional settings, including for therapy and mental support, soft skills practice and development, remote business and creative collaboration.
North-Star Care (https://north-star.care/) provides tele-health medical addiction treatment through constantly evolving treatment protocols that include AI/machine learning, medication, VR peer support, wearable assessment, drink substitution, nootropic and nutraceutical supplements. NSC is disrupting the paradigm and changing how people with alcohol use disorder (AUD) receive care on an ongoing basis while reducing barriers for participation and recovery.
Foretell and NSC will develop a robust roadmap of VR experiences and tools to be integrated with NSC's mobile application and administrative system, supporting biometric authentication, secured protocols, and by invitation-only sessions. This includes VR environments for support group and 1x1 sessions, customizable avatar representation, social interaction and activities (e.g. mindfulness exercises, games), shareable media (e.g. documents, 360 and 2D videos), and remote communication through spatial audio, and non-verbal cues (e.g. body movement, hand gestures). The companies will also conduct studies and customer focus groups to continually evolve and optimize the use of VR for treatment of alcohol use disorder through social engagement, guidance, and practice from anywhere.
Amanda Wilson, MD and CEO of NSC said, "We believe that VR technology will play a vital role in enhancing treatment of substance use disorder by providing an immersive and engaging tool for remote peer support and clinical guidance. As we look to disrupt traditional AUD treatment practices, our engagement with Foretell Reality provides the pathway to innovate and evolve our comprehensive, team based virtual treatment protocols to deliver a state-of-the-art medical program to help our patients".
Dror Goldberg, General Manager of Foretell Reality and Glimpse's VP Product commented, "NSC offers an innovative virtual alcohol treatment program, and we are thrilled to work with their highly-experienced team to address this important mission. By utilizing Foretell Reality's platform to deploy and manage specialized VR experiences, clinicians and participants have access to the unique capabilities that VR now allows in order to enhance the efficacy of therapy, support and mentoring techniques for those suffering from AUD. Foretell's immersive experiences provide a tangible group presence, while reducing traditional therapy barriers through anonymity and ease of access from the comfort of one's home. We look forward to a successful and long-term engagement with North-Star Care."
About Foretell Reality
Foretell Reality is a social virtual reality platform that supports many different types of avatars with varying degrees of realism and expression for different use cases including VR therapy and support, soft skills training, and business collaboration. For more details: https://foretellreality.com/
About North-Star Care
North-Star Care is a telehealth alcohol treatment program that is comprehensive, multidisciplinary, and personalized for each patient. A virtual alcohol treatment program that is an alternative to rehab. We are the most comprehensive, team-based medical program available. For more details: https://north-star.care/
About The Glimpse Group, Inc.
The Glimpse Group (NASDAQ: VRAR) is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software & services companies, and designed with the specific purpose
of cultivating companies in the emerging VR/AR industry. Glimpse's unique business model simplifies challenges faced by VR/AR companies and creates a robust ecosystem, while simultaneously providing investors an opportunity to invest directly into the emerging VR/AR industry via a diversified platform. For more information on The Glimpse Group, please visit www.theglimpsegroup.com
Safe Harbor Statement
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," and "would" or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely on management's best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.
Foretell Reality Contact:
Dror Goldberg
General Manager
dror@foretellreality.com
Glimpse Contact:
Maydan Rothblum
CFO & COO
The Glimpse Group, Inc.
maydan@theglimpsegroup.com
Investor Relations:
Mark Schwalenberg, CFA
MZ Group - North America
312-261-6430
Glimpse@mzgroup.us
www.mzgroup.us
SOURCE: The Glimpse Group, Inc.
View source version on accesswire.com:
https://www.accesswire.com/656063/The-Glimpse-Group-and-North-Star-Care-Announce-a-Multiyear-Virtual-Reality-Software-and-Services-Engagement
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom